首页> 外国专利> EPITOPE-BASED APPROACH FOR ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE

EPITOPE-BASED APPROACH FOR ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE

机译:基于表位的过敏治疗和抑制剂对克罗恩病的抑制剂

摘要

The present disclosure relates to pharmaceutical compounds and compositions and methods for treating an allergy and Crohn's disease. Methods for treating an allergy can include (a) predicting potential epitopes based proteomes of microbiome and that of an allergen, (b) filtering the potential epitopes obtained in step a) to result in a list of epitopes; and (c) reengineering the list of epitopes obtained in step b) to result in the new epitope. Methods for treating Crohn's disease can include (a), identifying one or more binding regions of an HLA class II protein and/or hemagglutinin to I2 superantigen; (b) determining a first peptide sequence corresponding to the one or more binding regions, and (c) producing a peptide inhibitor having a second peptide sequence that is a mutation of the first peptide sequence, wherein the second peptide sequence has a stronger binding affinity to the I2 superantigen than the first peptide sequence.
机译:本公开涉及药物化合物和组合物及其治疗过敏和克罗恩病的方法。 治疗过敏的方法可以包括(a)预测基于微生物组的潜在表位和过敏原的蛋白质组,(b)过滤在步骤a中获得的潜在表位,以导致表位列表; (c)重新进入在步骤b)中获得的表位列表,以导致新表位。 治疗克罗恩病的方法可以包括(a),鉴定HLA类II蛋白的一种或多种结合区域和/或Hemagglutinin至I2超剧蛋白; (b)确定对应于一个或多个结合区域的第一肽序列,(c)产生具有第二肽序列的肽抑制剂,其是第一肽序列的突变,其中第二肽序列具有更强的结合亲和力 到I2超抗原而不是第一个肽序列。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号